Symbole graficzne aparatów, maszyn i urządzeń przemysłu chemicznego
Antineoplastics
1
Reactions 1449 - 27 Apr 2013 S Antineoplastics Chronic kidney disease: 14 case reports Fourteen women, aged 39–69 years, were identified from a retrospective review after they developed chronic kidney disease (CKD) while receiving antineoplastics for recurrent ovarian cancer. Nine patients died. All patients had received liposomal doxorubicin for 3–66 months when stage 3 CKD was diagnosed, with cumulative doses of 460–2200mg/m 2 [dosage details incomplete; routes not stated]. The first sign of CKD was hypertension for most patients. Nine women progressed to either stage 4 or 5 CKD; two of these patients had pre-existing renal dysfunction that was stage <3 at the start of treatment. In addition to liposomal doxorubicin, the women had also received various treatment protocols that included carboplatin, either IV or intraperitoneal cisplatin, bevacizumab, oxaliplatin or gemcitabine [dosages and durations of treatments to reaction onsets not stated; some routes not stated]. Renal biopsy findings for three patients, who had stage 5 CKD, showed thrombotic microangiopathy. Two patients received haemodialysis, with one of these also receiving corticosteroids and plasmapheresis. Four women continued to have rising creatinine levels; two of these patients discontinued treatment. At last follow-up, one woman had stable creatinine levels and another was clinically stable. One woman developed unilateral hydronephrosis, while another woman died from end-stage renal disease and congestive heart failure. One woman had developed cancer progression at last follow-up, while eight patients had died as a result of disease. Author comment: "[O]ur findings suggest that platinums, [liposomal doxorubicin] (in large cumulative doses), bevacizumab, and possibly gemcitabine may result in cumulative kidney damage." Kwa M, et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. Oncologist 17: 1534-1540, No. 12, Dec 2012. Available from: URL: http://dx.doi.org/10.1634/theoncologist.2011-0422 - USA 803085905 1 Reactions 27 Apr 2013 No. 1449 0114-9954/10/1449-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1449 - 27 Apr 2013
SAntineoplastics
Chronic kidney disease: 14 case reportsFourteen women, aged 39–69 years, were identified from a
retrospective review after they developed chronic kidneydisease (CKD) while receiving antineoplastics for recurrentovarian cancer. Nine patients died.
All patients had received liposomal doxorubicin for3–66 months when stage 3 CKD was diagnosed, withcumulative doses of 460–2200mg/m2 [dosage detailsincomplete; routes not stated]. The first sign of CKD washypertension for most patients. Nine women progressed toeither stage 4 or 5 CKD; two of these patients had pre-existingrenal dysfunction that was stage <3 at the start of treatment. Inaddition to liposomal doxorubicin, the women had alsoreceived various treatment protocols that includedcarboplatin, either IV or intraperitoneal cisplatin,bevacizumab, oxaliplatin or gemcitabine [dosages anddurations of treatments to reaction onsets not stated; someroutes not stated]. Renal biopsy findings for three patients,who had stage 5 CKD, showed thrombotic microangiopathy.
Two patients received haemodialysis, with one of these alsoreceiving corticosteroids and plasmapheresis. Four womencontinued to have rising creatinine levels; two of these patientsdiscontinued treatment. At last follow-up, one woman hadstable creatinine levels and another was clinically stable. Onewoman developed unilateral hydronephrosis, while anotherwoman died from end-stage renal disease and congestiveheart failure. One woman had developed cancer progressionat last follow-up, while eight patients had died as a result ofdisease.
Author comment: "[O]ur findings suggest that platinums,[liposomal doxorubicin] (in large cumulative doses),bevacizumab, and possibly gemcitabine may result incumulative kidney damage."Kwa M, et al. Is renal thrombotic angiopathy an emerging problem in thetreatment of ovarian cancer recurrences?. Oncologist 17: 1534-1540, No. 12, Dec2012. Available from: URL: http://dx.doi.org/10.1634/theoncologist.2011-0422 -USA 803085905
1
Reactions 27 Apr 2013 No. 14490114-9954/10/1449-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
